Enlivex Therapeutics (NASDAQ:ENLV) Rating Reiterated by HC Wainwright

Enlivex Therapeutics (NASDAQ:ENLV)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $7.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 451.18% from the stock’s current price.

Enlivex Therapeutics Price Performance

NASDAQ ENLV opened at $1.27 on Tuesday. The company has a market cap of $23.58 million, a price-to-earnings ratio of -0.81 and a beta of 1.02. The stock’s fifty day moving average price is $3.30 and its 200 day moving average price is $2.54. Enlivex Therapeutics has a 1 year low of $1.15 and a 1 year high of $4.59.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.